Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,003 matching trials from the live ClinicalTrials.gov search.
Filters: "metabolic syndrome" Clear all
Completed Not applicable Interventional Results available

Spinal Cord Injury Exercise and Nutrition Conceptual Engagement

NCT03495986
View directory record Official record
Conditions
Spinal Cord Injuries, Metabolic Syndrome, Dietary Modification, Paraplegia, Tetraplegia
Interventions
Functional Electrical Stimulation Leg Cycle Ergometry, Diet
Device · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 11, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

NCT06488105
View directory record Official record
Conditions
Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
Interventions
Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, Outpatient Followup
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 11, 2026, 6:33 PM EDT
Recruiting No phase listed Observational

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC

NCT05825131
View directory record Official record
Conditions
Sanfilippo Syndrome Type C
Interventions
Not listed
Lead sponsor
Phoenix Nest
Industry
Eligibility
12 Months and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions

NCT05165186
View directory record Official record
Conditions
Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild, Dementia Moderate, Dementia Severe, Caregiver Burnout, Caregiver Stress Syndrome
Interventions
Video Intervention Arm
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resveratrol and the Metabolic Syndrome

NCT01714102
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolic Syndrome
Interventions
Placebo, Resveratrol
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
30 Years to 60 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 11, 2026, 6:33 PM EDT
Not yet recruiting Phase 2 Interventional

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

NCT07812181
View directory record Official record
Conditions
Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Jonathan Santoro
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome

NCT02153983
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Colchicine 0.6Mg Cap, Placebo capsules given, Colchicine 0.6Mg Tab
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 11, 2026, 6:33 PM EDT
Terminated Phase 3 Interventional Results available

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

NCT03563053
View directory record Official record
Conditions
Ataxia Telangiectasia, Genetic Syndrome
Interventions
EryDex System
Combination Product
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 11, 2026, 6:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Exercise and Carotid Artery Function in Metabolic Syndrome

NCT07430839
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
exercise, Diagnostics, Inhaled CO2-mixed air
Behavioral · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Terminated No phase listed Observational

Cardiovascular Implications of COVID-19

NCT04435457
View directory record Official record
Conditions
SARS-CoV 2, SARS Pneumonia, COVID-19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Cardiac Complication
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 11, 2026, 6:33 PM EDT
Not listed Phase 2 Interventional

Genetic Counseling and Lifestyle Change for Diabetes Prevention

NCT01034319
View directory record Official record
Conditions
Pre-diabetes, Overweight, Metabolic Syndrome
Interventions
Diabetes Genetic Counseling, No genetic counseling
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Not applicable Interventional

Atrantil for Intestinal Bacterial Overgrowth

NCT04755673
View directory record Official record
Conditions
Irritable Bowel Syndrome, Bacterial Overgrowth Syndrome, SIBO
Interventions
Atrantil (Medical Food)
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Not applicable Interventional

Long COVID-19 Syndrome Lifestyle Intervention Study

NCT05836402
View directory record Official record
Conditions
Long COVID-19 Syndrome
Interventions
Low carbohydrate diet intervention
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

NCT00637572
View directory record Official record
Conditions
HIV Infections, Cachexia, Anorexia, AIDS Wasting Syndrome, HIV Wasting Syndrome
Interventions
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 11, 2026, 6:33 PM EDT
Terminated Not applicable Interventional

Piloting Diet and Exercise Interventions in Older Hispanics With Diabetes

NCT04132739
View directory record Official record
Conditions
Diabetes, Senior Syndrome, Frailty
Interventions
Diet, Exercise, Diet and exercise
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
60 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Miami, Florida • Sweetwater, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional

Watermelon Supplementation and Arterial Stiffness

NCT01185041
View directory record Official record
Conditions
Hypertension
Interventions
Watermelon Extract
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 11, 2026, 6:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

NCT05078866
View directory record Official record
Conditions
Colorectal Carcinoma, Lynch Syndrome
Interventions
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

Epcoritamab and Rituximab for First-line Follicular Lymphoma

NCT05783609
View directory record Official record
Conditions
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Epcoritamab, Rituximab
Drug
Lead sponsor
Reid Merryman, MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

NCT00224055
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Phase 1 Interventional

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

NCT00000768
View directory record Official record
Conditions
Colitis, HIV Infections
Interventions
Glutamic acid hydrochloride, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 6:33 PM EDT
Active, not recruiting No phase listed Observational

Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes

NCT02371135
View directory record Official record
Conditions
Lynch Syndrome, Hereditary Colonic Polyposis Syndromes
Interventions
colonic biopsies, questionnaires
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 11, 2026, 6:33 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 11, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Vedolizumab Induction May Prevent Celiac Enteritis

NCT02929316
View directory record Official record
Conditions
Celiac Disease
Interventions
Vedolizumab
Drug
Lead sponsor
AGA Clinical Research Associates, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 11, 2026, 6:33 PM EDT